Targeted Immunomodulator Agents 2017 Archive
eculizumab (Soliris®) | ||
---|---|---|
PA Criteria:
|
||
Erythropoietin Stimulating Agents |
romiplostim (Nplate®) | ||
---|---|---|
PA Criteria:
|
Tier 1 |
Tier 2 |
Tier 3 |
DMARDs appropriate to disease state:
|
|
|
*For Cosentyx™ (secukinumab) only a trial of Humira® from the available Tier-2 medications will be required.
methotrexate injection (Rasuvo®/Otrexup™) | ||
---|---|---|
PA Criteria:
|
mercaptopurine oral solution (Purixan®) |
---|
PA Criteria:
|
PA Criteria:
|
natalizumab (Tysabri®) | ||
---|---|---|
PA Criteria:
Prior Authorization Forms |
rilonacept (Arcalyst®) |
||
---|---|---|
PA Criteria:
|
tbo-filgrastim (Granix®), and filgrastim-sndz (Zarxio™) | ||
---|---|---|
PA Criteria
Prior Authorization Forms |
Berinert® (C1 esterase inhibitor), Kalbitor® (ecallentide), and Firazyr® (icatibant) PA Criteria:
Cinryze® (C1 Esterase Inhibitor) and Haegarda® (C1 Esterase Inhibitor) Approval Criteria:
Prior Authorization Forms |
Respiratory Agents | ||
---|---|---|
omalizumab (Xolair®) | ||
palivizumab (Synagis®) | ||
reslizumab (Cinqair®) |
denosumab (Xgeva®) *Medical billing only |
teriparatide (Forteo®) |
dupilumab injection (Dupixent®) | ||
---|---|---|
PA Criteria:
|
botulinum toxins injections (Botox® Myobloc® Dysport® Xeomin®)*Medical billing only | ||
---|---|---|
Botulinum injections require a Prior Authorization for all diagnoses. Covered diagnoses for all products
Botox® only criteria (effective April 24, 2013) Consideration for approval requires the following critria for Botox for Prevention of Migraine Headaches (other botulinum toxins will not be approved for this use):
Consideration for approval requires the following criteria for Botox® for Non-Neurogenic Overactive Bladder (other botulinum toxins will not be approved for this use):
Consideration for approval requires the following criteria for Botox for Neurogenic Overactive Bladder (other botulinum toxins will not be approved for this use):
|
If you have questions please call the Pharmacy Help Desk at (800) 522-0114 option 4 or (405) 522-6205 option 4.